HEALTH OF WOMAN. 2020.9-10(155-156): 107-113; doi 10.15574/HW.2020.155-156.107
Skritskaya T. V.
SNPE «Regional Center of Oncology», Kharkiv

In modern gynecology, hormone-dependent pathology is one of the most significant problems. The importance of solving this problem is due to the significant prevalence of this pathology, its long-term recurrent course and the presence of a medico-social task of preserving the reproductive function of patients. The age of women who develop dyshormonal diseases is already 30–35 years old, which leads to premature loss of reproductive function, an increase in the frequency of surgical interventions.
The systemic nature of the lesion in dyshormonal pathology is due to the common links of pathogenesis. The leading factor in the pathogenesis of hormone-dependent pathology is absolute or relative hyperestrogenism. Menstrual disorders (MD) is one of the most overlooked problems in modern gynecology. Over the past decade, an increase in the frequency of MD in women of reproductive age has been noted in the world by almost 11 times. In the structure of gynecological morbidity, according to most authors, MD s account for about 60% of all dyshormonal disorders, which often lead to an underestimation of future not only reproductive, but also general somatic problems: from miscarriage and infertility to the formation of both benign and malignant tumors in the female organism.
Keywords: hormone-dependent pathology, menstrual disorders, estrogens, progesterone, treatment, indole-3-carbinol, rod extract, Agidol.

REFERENCES

1. Clemons M, Goss P. 2001. Estrogen and risk of breast cancer, N. Engl. J. Med. 344.4: 276-286. https://doi.org/10.1056/NEJM200101253440407;PMid:11172156

2. Dalessandri KM, Firestone GL et al. 2004. Pilot Study: Effect of 3-Diindolylmethane Supplements on hormone metabolites in Postmenstrual women with history of ear-ly-stage breast cancer. Nutrition and cancer. 50(2):161-167. https://doi.org/10.1207/s15327914nc5002_5; PMid:15623462

3. Andreeva EN, Hamoshina MB, Rudneva OD. 2012. Prolaktin i molochnyie zhelezy. Ginekologiya 1:12-16.

4. Astahov VM. 2011. Negormonalnaya patogeneticheski obosnovannaya terapiya miomy matki. Zdorove zhenschiny 3(59):112-117.

5. Voloshyna NM, Pashchenko SM, Shchurov MF ta in. 2013. Nehormonalna terapiia proliferatyvnykh protsesiv molochnoi zalozy ta endometriia. Zdorove zhenshchyny 1(77):94-98.

6. Zaporozhan VN, Tatarchuk TF, Dubinina VG, Kosey NV. 2012. Sovremennaya diagnostika i lechenie giperplasticheskih protsessov endometriya. Reproduktivnaya endokrinologiya 1(3):5-12.

7. Kaminskiy VV, Boris EN. 2012. Konservativnoe lechenie miomyi matki, sochetannoy s prostoy neatipicheskoy giperplaziey endometriya. Zbirnyk naukovyh prats. K.

8. Kiselev VI, Sidorova IS, Unanyan AL. 2011. Giperplasticheskie protsessyi organov reproduktivnoy sistemyi: teoriya i praktika. M, ND «Medpraktika»:468.

9. Kiselev VI, Lyashenko AA. 2005. Indol – regulyator proliferativnyih protsessov v organah reproduktivnoy sistemyi. M:48.

10. Kohanevich EV, Mitskevich EP, Manzhura EP i dr. 2006. Giperplasticheskie protsessy endometriya. Aktualnyie voprosy akusherstva, ginekologii i reproduktologii. M:286-303.

11. Reznichenko GI, Paschenko SM, Potebnya VYu i dr. 2008. Problemyi, dostizheniya i perspektivyi razvitiya mediko-biologicheskih nauk i prakticheskogo zdravoohraneniya. 144;ch. III:215-218.

12. Stepankovskaya GK, Boroda AN. 2001. Giperplasticheskie protsessyi endometriya: novyie podhodyi v lechenii. Zbirnyk naukovih prats asotsiatsii akusheriv-ginekologiv Ukraini: 593-595.